SCHEMBL8904149

SCHEMBL8904149

O=C(CCl)N1CCC(CCCc2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.55
HDAC3 O15379 2/20 0.55
HDAC4 P56524 2/20 0.55
HDAC1 Q13547 2/20 0.55
HDAC7 Q8WUI4 2/20 0.55
HDAC2 Q92769 2/20 0.55
HDAC10 Q969S8 2/20 0.55
HDAC11 Q96DB2 2/20 0.55
HDAC8 Q9BY41 2/20 0.55
HDAC9 Q9UKV0 2/20 0.55
HDAC5 Q9UQL6 2/20 0.55
SLC18A3 Q16572 1/20 0.53
FAAH O00519 2/20 0.52
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
POLB P06746 1/20 0.51
YAP1 P46937 1/20 0.51
TEAD4 Q15561 1/20 0.51
OPRK1 P41145 1/20 0.51
KDM1A O60341 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8905029 0.86 HDAC6 (0.55) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL11538421 0.86 SLC18A3 (0.56) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL9051255 0.85 SLC18A3 (0.58) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL8539110 0.84 FAAH (0.64) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL27373891 0.83 SLC18A3 (0.56) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL2243090 0.82 ALDH1A1 (0.64) FAAHALDH1A1POLBRAB9A
SCHEMBL25242855 0.82 HDAC3 (0.66) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL10720231 0.82 CYP2C9 (0.58) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL10724420 0.82 HDAC3 (0.62) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL7401017 0.82 HDAC6 (0.54) HDAC6HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368608-A1 SELECTIVE HDAC6 INHIBITOR ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2025-12-04 US disclosed
WO-2022129256-A1 SELECTIVE HDAC6 INHIBITOR ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2022-06-23 WO disclosed
US-5618808-A Benzothiazepine and benzoxazepine derivatives as cholecystokinin receptor antagonists PFIZER, INC. (US) 1997-04-08 US disclosed
EP-0648213-A1 BENZOTHIAZEPINE AND BENZOXAZEPINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS PFIZER INC. (US) 1995-04-19 EP disclosed
WO-1994001421-A1 BENZOTHIAZEPINE AND BENZOXAZEPINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS PFIZER INC. (US) 1994-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368608-A1 SELECTIVE HDAC6 INHIBITOR HDAC6, HDAC3, HDAC1 HDAC6 1/4885HDAC3 2/4885HDAC4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.